Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.

  • Boris Rosenkranz
  • Published 1996 in
    Hormone and metabolic research = Hormon- und…

Abstract

The pharmacokinetics of the sulfonylurea, glimepiride, in risk groups of NIDDM patients are reviewed with regard to pharmacokinetic-effect relationships. A variety of factors, such as regulatory processes, glucose absorption, insulin sensitivity, might prevent the definition of a clear concentration-effect relationship for sulfonylureas. However, when these… (More)

Topics

Cite this paper

@article{Rosenkranz1996PharmacokineticBF, title={Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.}, author={Boris Rosenkranz}, journal={Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme}, year={1996}, volume={28 9}, pages={434-9} }